Mirum Historical Financial Ratios

MIRM Stock

USD 46.22 0.43 0.92%

Mirum Pharmaceuticals is lately reporting on over 122 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 82.42 will help investors to properly organize and evaluate Mirum Pharmaceuticals financial condition quickly.

Quick Ratio Current Ratio

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mirum Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.

About Mirum Financial Ratios Analysis

Mirum PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Mirum Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Mirum financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Mirum Pharmaceuticals history.

Mirum Pharmaceuticals Financial Ratios Chart

At this time, Mirum Pharmaceuticals' Debt To Equity is very stable compared to the past year. As of the 29th of November 2024, Capex Per Share is likely to grow to 0.52, while Free Cash Flow Yield is likely to drop (0.08).

Price To Sales Ratio Days Sales Outstanding Free Cash Flow Yield Ev To Sales Inventory Turnover Sales General And Administrative To Revenue

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Mirum Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Mirum Pharmaceuticals sales, a figure that is much harder to manipulate than other Mirum Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Inventory Turnover

A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.

Most ratios from Mirum Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Mirum Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mirum Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.At this time, Mirum Pharmaceuticals' Debt To Equity is very stable compared to the past year. As of the 29th of November 2024, Capex Per Share is likely to grow to 0.52, while Free Cash Flow Yield is likely to drop (0.08).

	2022	2023	2024 (projected)
Payables Turnover	1.42	6.34	6.66
Days Of Inventory On Hand	164.15	173.13	230.08

Payables Turnover Days Of Inventory On Hand

Mirum Pharmaceuticals fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio
Price To Sales Ratio		-0.69	-0.89	-0.51	0.19	0.39	0.04	-0.69	1.0	0.41	0.17	-0.86	0.75	0.94	-0.9	0.99	-0.27	-0.61	-0.83	-0.61	-0.53	0.9	-0.3	0.71	-0.6	-0.6
Ptb Ratio	-0.69		0.61	0.92	-0.75	-0.88	0.45	1.0	-0.69	-0.89	-0.37	0.58	-0.96	-0.63	0.65	-0.68	0.75	0.98	0.84	0.98	0.96	-0.89	0.86	-0.97	0.98	0.96
Days Sales Outstanding	-0.89	0.61		0.53	-0.2	-0.38	-0.08	0.61	-0.89	-0.39	-0.13	0.97	-0.67	-0.97	0.74	-0.9	0.28	0.55	0.75	0.55	0.5	-0.8	0.26	-0.61	0.54	0.55
Book Value Per Share	-0.51	0.92	0.53		-0.68	-0.84	0.23	0.92	-0.51	-0.82	-0.07	0.5	-0.91	-0.52	0.47	-0.51	0.93	0.96	0.58	0.96	0.94	-0.73	0.79	-0.81	0.96	0.93
Free Cash Flow Yield	0.19	-0.75	-0.2	-0.68		0.96	-0.72	-0.75	0.19	0.96	0.54	-0.26	0.67	0.25	-0.07	0.22	-0.51	-0.75	-0.61	-0.75	-0.86	0.58	-0.95	0.71	-0.75	-0.84
Operating Cash Flow Per Share	0.39	-0.88	-0.38	-0.84	0.96		-0.56	-0.88	0.4	0.99	0.39	-0.43	0.84	0.43	-0.25	0.42	-0.67	-0.9	-0.69	-0.9	-0.97	0.73	-0.97	0.81	-0.9	-0.95
Capex To Depreciation	0.04	0.45	-0.08	0.23	-0.72	-0.56		0.45	0.04	-0.64	-0.91	-0.1	-0.22	0.08	0.03	0.05	0.12	0.37	0.51	0.37	0.45	-0.26	0.7	-0.56	0.37	0.39
Pb Ratio	-0.69	1.0	0.61	0.92	-0.75	-0.88	0.45		-0.69	-0.89	-0.37	0.58	-0.96	-0.63	0.65	-0.68	0.75	0.98	0.84	0.98	0.96	-0.89	0.86	-0.97	0.98	0.96
Ev To Sales	1.0	-0.69	-0.89	-0.51	0.19	0.4	0.04	-0.69		0.41	0.17	-0.86	0.75	0.94	-0.9	0.99	-0.27	-0.61	-0.83	-0.61	-0.53	0.9	-0.3	0.71	-0.6	-0.6
Free Cash Flow Per Share	0.41	-0.89	-0.39	-0.82	0.96	0.99	-0.64	-0.89	0.41		0.49	-0.42	0.83	0.43	-0.29	0.43	-0.63	-0.89	-0.74	-0.89	-0.96	0.75	-0.97	0.85	-0.89	-0.94
Roic	0.17	-0.37	-0.13	-0.07	0.54	0.39	-0.91	-0.37	0.17	0.49		-0.07	0.18	0.1	-0.25	0.14	0.15	-0.23	-0.62	-0.22	-0.29	0.36	-0.49	0.55	-0.22	-0.27
Inventory Turnover	-0.86	0.58	0.97	0.5	-0.26	-0.43	-0.1	0.58	-0.86	-0.42	-0.07		-0.65	-0.99	0.61	-0.9	0.24	0.54	0.74	0.54	0.52	-0.78	0.3	-0.55	0.54	0.57
Net Income Per Share	0.75	-0.96	-0.67	-0.91	0.67	0.84	-0.22	-0.96	0.75	0.83	0.18	-0.65		0.71	-0.67	0.75	-0.73	-0.95	-0.78	-0.94	-0.93	0.93	-0.75	0.89	-0.94	-0.96
Days Of Inventory On Hand	0.94	-0.63	-0.97	-0.52	0.25	0.43	0.08	-0.63	0.94	0.43	0.1	-0.99	0.71		-0.73	0.96	-0.26	-0.58	-0.79	-0.58	-0.54	0.85	-0.31	0.62	-0.58	-0.6
Payables Turnover	-0.9	0.65	0.74	0.47	-0.07	-0.25	0.03	0.65	-0.9	-0.29	-0.25	0.61	-0.67	-0.73		-0.84	0.29	0.54	0.73	0.54	0.42	-0.8	0.2	-0.72	0.53	0.48
Capex To Revenue	0.99	-0.68	-0.9	-0.51	0.22	0.42	0.05	-0.68	0.99	0.43	0.14	-0.9	0.75	0.96	-0.84		-0.25	-0.61	-0.83	-0.61	-0.55	0.89	-0.32	0.68	-0.61	-0.61
Cash Per Share	-0.27	0.75	0.28	0.93	-0.51	-0.67	0.12	0.75	-0.27	-0.63	0.15	0.24	-0.73	-0.26	0.29	-0.25		0.85	0.3	0.85	0.79	-0.46	0.67	-0.62	0.85	0.76
Pocfratio	-0.61	0.98	0.55	0.96	-0.75	-0.9	0.37	0.98	-0.61	-0.89	-0.23	0.54	-0.95	-0.58	0.54	-0.61	0.85		0.74	1.0	0.98	-0.82	0.88	-0.91	1.0	0.97
Interest Coverage	-0.83	0.84	0.75	0.58	-0.61	-0.69	0.51	0.84	-0.83	-0.74	-0.62	0.74	-0.78	-0.79	0.73	-0.83	0.3	0.74		0.73	0.73	-0.92	0.67	-0.9	0.74	0.75
Capex To Operating Cash Flow	-0.61	0.98	0.55	0.96	-0.75	-0.9	0.37	0.98	-0.61	-0.89	-0.22	0.54	-0.94	-0.58	0.54	-0.61	0.85	1.0	0.73		0.98	-0.82	0.87	-0.9	1.0	0.97
Pfcf Ratio	-0.53	0.96	0.5	0.94	-0.86	-0.97	0.45	0.96	-0.53	-0.96	-0.29	0.52	-0.93	-0.54	0.42	-0.55	0.79	0.98	0.73	0.98		-0.8	0.93	-0.88	0.98	0.99
Days Payables Outstanding	0.9	-0.89	-0.8	-0.73	0.58	0.73	-0.26	-0.89	0.9	0.75	0.36	-0.78	0.93	0.85	-0.8	0.89	-0.46	-0.82	-0.92	-0.82	-0.8		-0.63	0.89	-0.82	-0.86
Income Quality	-0.3	0.86	0.26	0.79	-0.95	-0.97	0.7	0.86	-0.3	-0.97	-0.49	0.3	-0.75	-0.31	0.2	-0.32	0.67	0.88	0.67	0.87	0.93	-0.63		-0.81	0.88	0.89
Roe	0.71	-0.97	-0.61	-0.81	0.71	0.81	-0.56	-0.97	0.71	0.85	0.55	-0.55	0.89	0.62	-0.72	0.68	-0.62	-0.91	-0.9	-0.9	-0.88	0.89	-0.81		-0.9	-0.88
Ev To Operating Cash Flow	-0.6	0.98	0.54	0.96	-0.75	-0.9	0.37	0.98	-0.6	-0.89	-0.22	0.54	-0.94	-0.58	0.53	-0.61	0.85	1.0	0.74	1.0	0.98	-0.82	0.88	-0.9		0.97
Pe Ratio	-0.6	0.96	0.55	0.93	-0.84	-0.95	0.39	0.96	-0.6	-0.94	-0.27	0.57	-0.96	-0.6	0.48	-0.61	0.76	0.97	0.75	0.97	0.99	-0.86	0.89	-0.88	0.97

Click cells to compare fundamentals

Mirum Pharmaceuticals Account Relationship Matchups

Mirum Pharmaceuticals fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Ptb Ratio	(8.06)	(2.55)	4.02	(1.68)	4.85	5.1
Book Value Per Share	5.67	6.82	3.96	4.2	6.08	3.5
Free Cash Flow Yield	(0.0703)	(0.2)	(0.31)	(0.18)	(0.0754)	(0.0792)
Operating Cash Flow Per Share	(1.71)	(3.53)	(4.38)	(3.55)	(1.74)	(1.82)
Pb Ratio	(8.06)	(2.55)	4.02	(1.68)	4.85	5.1
Free Cash Flow Per Share	(1.72)	(3.54)	(5.01)	(3.56)	(2.23)	(2.34)
Roic	0.83	0.61	(1.41)	0.32	(0.2)	(0.19)
Net Income Per Share	(2.29)	(4.09)	(2.77)	(4.01)	(4.0)	(4.2)
Cash Per Share	10.64	9.18	5.16	4.48	7.0	5.17
Pocfratio	(14.32)	(4.95)	(3.64)	(5.49)	(17.01)	(17.86)
Capex To Operating Cash Flow	(0.007139)	(0.002526)	(0.14)	(0.002314)	(0.28)	(0.3)
Pfcf Ratio	(14.22)	(4.94)	(3.19)	(5.48)	(13.26)	(13.92)
Income Quality	0.75	0.86	1.58	0.89	0.43	0.61
Roe	0.75	0.6	(0.7)	0.35	(0.66)	(0.62)
Ev To Operating Cash Flow	(10.86)	(3.39)	(3.43)	(5.28)	(17.32)	(18.19)
Pe Ratio	(10.73)	(4.27)	(5.76)	(4.86)	(7.39)	(7.75)
Return On Tangible Assets	(0.36)	(0.43)	(0.3)	(0.46)	(0.42)	(0.44)
Ev To Free Cash Flow	(10.78)	(3.38)	(3.0)	(5.27)	(13.49)	(14.17)
Net Debt To E B I T D A	2.61	1.36	0.44	0.21	(0.16)	(0.15)
Current Ratio	9.13	12.8	3.91	2.94	4.45	4.23
Tangible Book Value Per Share	5.67	6.82	3.35	2.46	(0.1)	(0.0989)
Graham Number	12.51	25.12	15.72	32.36	23.39	14.91
Shareholders Equity Per Share	(3.04)	(6.86)	3.96	(11.61)	6.08	6.39
Capex Per Share	0.0122	0.00891	0.63	0.008215	0.49	0.52
Graham Net Net	9.93	6.46	(0.48)	(1.13)	(1.21)	(1.15)
Enterprise Value Over E B I T D A	(8.19)	(2.95)	(6.96)	(5.18)	(9.0)	(9.45)
Price Earnings Ratio	(10.73)	(4.27)	(5.76)	(4.86)	(7.39)	(7.75)
Price Book Value Ratio	(8.06)	(2.55)	4.02	(1.68)	4.85	5.1
Price To Operating Cash Flows Ratio	(14.32)	(4.95)	(3.64)	(5.49)	(17.01)	(17.86)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Mirum Pharmaceuticals is a strong investment it is important to analyze Mirum Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Mirum Pharmaceuticals' future performance. For an informed investment choice regarding Mirum Stock, refer to the following important reports:

How To Invest In Mirum

Details

Is Mirum Stock a good investment?

Details

What is Mirum Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.

You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.08)

Revenue Per Share

6.513

Quarterly Revenue Growth

0.894

Return On Assets

(0.09)

Return On Equity

(0.40)

The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Mirum Historical Financial Ratios

About Mirum Financial Ratios Analysis

Mirum Pharmaceuticals Financial Ratios Chart

Price To Sales Ratio

Free Cash Flow Yield

Ev To Sales

Inventory Turnover

Mirum Pharmaceuticals fundamentals Correlations

Mirum Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Mirum Pharmaceuticals fundamentals Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Capex To Operating Cash Flow	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Capex To Operating Cash Flow
Capex To Revenue	+ 0.99	Price To Sales Ratio

Days Of Inventory On Hand	- 0.99	Inventory Turnover
Income Quality	- 0.97	Free Cash Flow Per Share
Roe	- 0.97	Pb Ratio
Income Quality	- 0.97	Operating Cash Flow Per Share
Pfcf Ratio	- 0.97	Operating Cash Flow Per Share
Days Of Inventory On Hand	- 0.97	Days Sales Outstanding